NCT00461058 - A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Actos

Titrated to an individual maximum tolerated dose up to 45mg p.o. daily

DRUG

aleglitazar

Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily

Trial Locations (45)

1151

Kiev

2091

Kiev

11650

Mexico City

20475

Bucharest

31096

Haifa

32216

Jacksonville

42000

Pachuca

44195

Cleveland

44281

Kfar Saba

50452

Bucharest

55455

Minneapolis

61178

Kharkiv

64000

Monterrey

70458

Slidell

72401

Jonesboro

73112

Oklahoma City

74104

Tulsa

78278

Ashkelon

83003

Donetsk

83114

Donetsk

90822

Long Beach

92354

Loma Linda

95608

Carmichael

100097

Ploieşti

123436

Moscow

125101

Moscow

127018

Moscow

127299

Moscow

130083

Târgovişte

150062

Yaroslavl

191025

Saint Petersburg

198205

Saint Petersburg

199106

Saint Petersburg

310037

Arad

410028

Saratov

410169

Oradea

430123

Baia Mare

600114

Bacau

SIN80020

Culiacán

JAL44340

Guadalajara

EMEX52140

Metepec

DF7060

Mexico City

SLP78250

San Luis Potosí City

010242

Bucharest

02091

Kiev

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY